Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 3/20 | 0.57 |
| ▸ | ATF1 | P18846 | 10/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 10/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11612611 | 0.83 | POLB (0.62) | POLBKDM4EALDH1A1TDP1EGLN1 | |
| SCHEMBL30617280 | 0.80 | KDM4E (0.71) | XPO1ATF1NFKB1KDM4EJUN | |
| SCHEMBL3381334 | 0.79 | CNR2 (0.72) | CNR2 | |
| SCHEMBL8396850 | 0.76 | XPO1 (0.65) | XPO1ATF1NFKB1JUNNFKB2 | |
| SCHEMBL473934 | 0.76 | ATF1 (0.62) | XPO1ATF1NFKB1KDM4EALDH1A1 | |
| SCHEMBL6477545 | 0.75 | GAA (0.51) | NFKB1KDM4EALDH1A1JUNNFKB2 | |
| SCHEMBL5077116 | 0.75 | CNR2 (0.73) | ALDH1A1CNR2 | |
| SCHEMBL16814236 | 0.75 | POLB (0.52) | POLBALDH1A1TDP1EGLN1 | |
| SCHEMBL480176 | 0.75 | XPO1 (0.62) | XPO1ATF1NFKB1JUNNFKB2 | |
| SCHEMBL13069667 | 0.74 | CNR2 (0.58) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1539712-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-07 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| EP-1736470-A2 | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060247261-A1 | Pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| EP-1534687-A1 | PYRIMIDINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| WO-2004018434-A1 | PYRIMIDINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018433-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | XPO1 4783/4885ATF1 2368/4885NFKB1 159/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | XPO1 4616/4885ATF1 2604/4885NFKB1 704/4885 |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | XPO1 2221/4885ATF1 889/4885NFKB1 2405/4885 |
| US-20060247261-A1 | Pyrimidine compounds | CNR2, CNR1, P2RX5 | XPO1 1383/4885ATF1 1888/4885NFKB1 2047/4885 |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | XPO1 2382/4885ATF1 1190/4885NFKB1 2616/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | XPO1 3505/4885ATF1 225/4885NFKB1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.